For Medical Professionals

Industry News

Intratumor morphological heterogeneity of cancer is not related to chromosome aberrations
9/30/2015

Intratumor morphological heterogeneity (diversity) of breast cancer is not related to chromosome aberrations.

Launch of first UK charity dedicated to 36,000 women living with advanced breast cancer
9/30/2015

Second Hope (SecondHope.org.uk), the first UK charity to focus specifically on the needs of the 'forgotten women' living with advanced breast cancer - of which there are currently an estimated...

Scientists pioneer 3-D-printed drug delivering micro-needles
9/30/2015

Researchers have developed a new technique to produce a 3D 'micro-printed' array of needles capable of drug delivery.

Low-cost blood test good predictor of increased bleeding risk in pediatric trauma patients
9/30/2015

A team of researchers from the Trauma Program at Children's Hospital Los Angeles conclude that an admission hematocrit provides a reliable screening test for identifying pediatric patients who are at...

Aspirin may double survival for cancer patients
9/29/2015

Patients with gastrointestinal cancers who took aspirin after diagnosis were more than twice as likely to survive as those who did not take the drug, a new study finds.

U.S. cervical cancer screening practices show room for improvement
9/29/2015

An analysis published in Annals of Internal Medicine shows that current U.S.

U.S. cervical cancer screening practices show room for improvement
9/29/2015

An analysis published in Annals of Internal Medicine shows that current U.S.

UC Davis researcher advocates ending Medicare coverage of controversial mammography tool
9/29/2015

A costly tool used on nearly all mammograms does not increase cancer detection rates and should no longer be covered by Medicare, argues Joshua Fenton, a family physician and comparative...

Targeted cancer treatment: new dual strategy halts cell division
9/29/2015

A team of researchers at the MedUni Vienna has confirmed in a recent study its new concept for the targeted treatment of ovarian cancer.

Positive safety and efficacy data in over 500 DC BeadM1 patients and compelling health economic data for TheraSphere announced
9/29/2015

BTG plc company has announced promising data for DC BeadM1™, supporting the efficacy and tolerability of doxorubicin-eluting DC BeadM1™ in the treatment of patients diagnosed with...